Study of extended-spectrum beta-lactamases and AmpC beta-lactamases producing Klebsiella from clinical samples in tertiary care hospital of Punjab

doi:10.5501/wjv.v15.i1.118602

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 1

This Article

(39)

(75)

(0)

(37)

(966)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Virology

ISSN

2220-3249

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Virol. Mar 25, 2026; 15(1): 118602
Published online Mar 25, 2026. doi: 10.5501/wjv.v15.i1.118602

Table 2 Antimicrobial susceptibility patterns of extended-spectrum beta-lactamases-producing vs non-extended-spectrum beta-lactamases-producing Klebsiella isolates, n (%)

Antibiotics	ESBL producers (n = 77)			Non ESBL producers (n = 53)			χ² statistics	P value
Antibiotics	Susceptible	Resistance	Intermediate	Susceptible	Resistance	Intermediate	χ² statistics	P value
Ampicillin	0 (0)	77 (100)	0 (0)	0 (0)	53 (100)	0 (0)	0	1
Amoxicillin	0 (0)	77 (100)	0 (0)	0 (0)	53 (100)	0 (0)	0	1
Amoxicillin-clavulanic acid	14 (18.2)	59 (76.6)	4 (5.2)	18 (33.9)	34 (64.1)	1 (1.9)	4.75	0.09
Cefotaxime	1 (1.3)	75 (97.4)	1 (1.3)	22 (41.5)	30 (56.6)	1 (1.9)	35.22	< 0.0001^a
Ceftazidime	1 (1.3)	76 (98.7)	0 (0)	23 (43.3)	30 (56.6)	0 (0)	37	< 0.0001^a
Ciproflaxacin	5 (6.5)	71 (92.2)	1 (1.3)	10 (18.9)	40 (75.4)	3 (5.6)	7.14	0.03^a
Gentamicin	46 (59.7)	31 (40.3)	0 (0)	35 (66.0)	17 (32.1)	1 (1.9)	2.22	0.33
Amikacin	38 (49.4)	35 (45.5)	4 (5.2)	25 (47.2)	23 (43.3)	5 (9.4)	0.88	0.64
Piperacillin-tazobactam	30 (39.0)	41 (53.2)	6 (7.8)	18 (34.0)	29 (54.7)	6 (11.3)	0.65	0.72
Meropenem	36 (46.8)	41 (53.2)	0 (0)	25 (47.2)	28 (52.8)	0 (0)	0	1
Imipenem	37 (48.1)	39 (50.6)	1 (1.3)	25 (47.2)	28 (52.8)	0 (0)	0.72	0.70
Nitrofurantoin¹	11 (78.6)	3 (21.4)	0 (0)	2 (15.4)	11 (84.6)	0 (0)	10.78	0.004^a
Norfloxacin¹	2 (14.3)	12 (85.7)	0 (0)	5 (38.5)	8 (61.5)	0 (0)	2.05	0.36

¹Norfloxacin and nitrofurantoin tested for urine specimens only (n = 14 extended-spectrum beta-lactamases producers; n = 13 non-extended-spectrum beta-lactamases producers).

^aP < 0.05.

EBSL: Extended-spectrum beta-lactamases.

Full Size Table

Citation: Kaur H, Arora S, Sharma V, Kaur K, Kamboj S. Study of extended-spectrum beta-lactamases and AmpC beta-lactamases producing Klebsiella from clinical samples in tertiary care hospital of Punjab. World J Virol 2026; 15(1): 118602
URL: https://www.wjgnet.com/2220-3249/full/v15/i1/118602.htm
DOI: https://dx.doi.org/10.5501/wjv.v15.i1.118602

Kaur H, Arora S, Sharma V, Kaur K, Kamboj S. Study of extended-spectrum beta-lactamases and AmpC beta-lactamases producing Klebsiella from clinical samples in tertiary care hospital of Punjab. World J Virol 2026; 15(1): 118602 [PMID: 41884455 DOI: 10.5501/wjv.v15.i1.118602]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.